Medtronic plc (MDT)

NYSE - NYSE Real Time Price. Currency in USD
86.41-0.33 (-0.38%)
As of 9:52 AM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close86.74
Bid86.71 x 400
Ask86.76 x 400
Day's Range86.36 - 87.46
52wk Range66.35 - 89.27
1y Target EstN/A
Market Cap119.41B
P/E Ratio (ttm)33.62
Avg Vol (3m)4,224,765
Dividend & Yield1.72 (1.98%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • FDA approves 'artificial pancreas' to manage diabetes
    Associated Press8 hours ago

    FDA approves 'artificial pancreas' to manage diabetes

    Federal regulators have approved a first-of-a-kind "artificial pancreas," a device that can help some diabetes patients manage their disease by constantly monitoring their blood sugar and delivering ...

  • The Wall Street Journal10 hours ago

    [$$] FDA Approves Medtronic’s New Automated Insulin Pump

    The U.S. Food and Drug Administration said it has approved an insulin pump by medical device company Medtronic that automatically manages glucose levels within a target range.

  • Reuters14 hours ago

    U.S. FDA approves Medtronic's 'artificial pancreas' for diabetes

    Medtronic Plc won U.S. approval on Wednesday for an "artificial pancreas" that is the first device to automatically deliver the right dose of insulin to patients with type 1 diabetes, freeing them from continually monitoring insulin levels throughout each day. The U.S. Food and Drug Administration, in its approval of the device, the MiniMed 670G, hailed it as a breakthrough. The device offers type 1 diabetics "greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin," Dr. Jeffrey Shuren, director of the FDA's medical device division, said in a statement.